Abstract
Aim: The aim of this study is to determine the efficacy and safety of the combination therapy of drug-eluting bead bronchial arterial chemoembolization plus anlotinib oral administration in the treatment of non-small-cell lung cancer (NSCLC).Methods: Consecutive data from 51 patients with advanced NSCLC were retrospectively collected from February 2018 to August 2019. All patients underwent drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) followed by anlotinib treatment. Overall survival (OS) and progression-free survival (PFS) were calculated and analyzed using the Kaplan–Meier method and log-rank test, and factors associated with OS and PFS were assessed by a Cox proportional hazards test. Treatment response at 30 days was assessed by enhanced computed tomography (CT), and then the objective response rate (ORR) and disease control rate (DCR) were calculated. Treatment-related adverse events (TRAEs) were also evaluated.Results: The median OS was 18.4 months (95% CI, 16.6–20.2 months), and the median PFS was 8.4 months (95% CI, 6.2–10.6 months). The ORR and DCR for the whole cohort were 21.6 and 100%, respectively, at 30 days after the first cycle of treatment. Most of the treatment-related adverse reactions were mild and moderate and included anorexia, hypertension, fatigue, and hand-foot syndrome. Only eight (15.7%) patients developed grade 3 TRAEs. No deaths or other serious adverse reactions occurred. Both TNM stage and brain metastasis were independent risk factors for OS and PFS.Conclusion: DEB-BACE concomitant with anlotinib has promising efficacy and tolerable toxicity in patients with advanced NSCLC.
Highlights
Lung cancer is the leading cause of cancer death worldwide, accounting for approximately 18.4% of all cancer deaths (Bray et al, 2018)
Overall survival (OS) and progression-free survival (PFS) were calculated and analyzed using the Kaplan–Meier method and log-rank test, and factors associated with OS and PFS were assessed by a Cox proportional hazards test
The median OS was 18.4 months, and the median PFS was 8.4 months
Summary
Lung cancer is the leading cause of cancer death worldwide, accounting for approximately 18.4% of all cancer deaths (Bray et al, 2018). Non-small-cell lung cancer (NSCLC) is the main histological type of lung cancer, accounting for approximately 83% of lung cancer cases. Chemotherapy with or without radiation remains the main treatment for patients with advanced NSCLC (stage III/IV). Many studies have demonstrated that bronchial artery chemoembolization (BACE) is more effective and less toxic than conventional chemotherapy in treating advanced NSCLC patients (Zhu et al, 2017; Liu et al, 2021). BACE is a combination technique of transcatheter arterial chemical infusion (TAI) followed by embolization, which is performed by injecting chemotherapy drugs and putting the embolization agents into the tumor-feeding arteries, promoting the clinical efficacy and reducing the systemic toxicity in patients with advanced NSCLC. Given the advantage of slow and sustained release of drugs, drug-eluting bead bronchial artery chemoembolization (DEB-BACE) has been developed and widely used in combination therapy for advanced NSCLC (Bie et al, 2019; Zeng et al, 2020)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
